72 related articles for article (PubMed ID: 7995763)
1. Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation.
Senan S
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):209-10. PubMed ID: 7995763
[No Abstract] [Full Text] [Related]
2. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
3. Targeting hypoxia in head and neck cancer.
Peters LJ
Acta Oncol; 2001; 40(8):937-40. PubMed ID: 11845958
[TBL] [Abstract][Full Text] [Related]
4. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
5. Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075).
Spiegel JF; Spear MA; Brown JM
Radiother Oncol; 1993 Jan; 26(1):79-81. PubMed ID: 8438092
[TBL] [Abstract][Full Text] [Related]
6. Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.
Bains LJ; Baker JH; Kyle AH; Minchinton AI; Reinsberg SA
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):957-65. PubMed ID: 19480975
[TBL] [Abstract][Full Text] [Related]
7. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice.
Cardinale RM; Dillehay LE; Williams JA; Tabassi K; Brem H; Lee DJ
Radiat Oncol Investig; 1998; 6(2):63-70. PubMed ID: 9572682
[TBL] [Abstract][Full Text] [Related]
8. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
[TBL] [Abstract][Full Text] [Related]
9. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
McKeown SR; Friery OP; McIntyre IA; Hejmadi MV; Patterson LH; Hirst DG
Br J Cancer Suppl; 1996 Jul; 27():S39-42. PubMed ID: 8763843
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie MJ; Brown JM
Cancer Res; 1993 Oct; 53(19):4633-6. PubMed ID: 8402639
[TBL] [Abstract][Full Text] [Related]
12. Potassium vasoactivity--a biphasic effect.
Boley SJ; Kamil N; Levowitz BS; Treiber WF; Agrawal GP; Veith FJ
Surgery; 1970 Feb; 67(2):350-4. PubMed ID: 5411300
[No Abstract] [Full Text] [Related]
13. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer.
Rischin D; Narayan K; Oza AM; Mileshkin L; Bernshaw D; Choi J; Hicks R; McClure B; Fyles A
Int J Gynecol Cancer; 2010 Jul; 20(5):827-33. PubMed ID: 20606530
[TBL] [Abstract][Full Text] [Related]
15. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
Kyle AH; Minchinton AI
Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma.
Sun JR; Brown JM
Cancer Res; 1989 Oct; 49(20):5664-70. PubMed ID: 2790784
[TBL] [Abstract][Full Text] [Related]
17. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
[TBL] [Abstract][Full Text] [Related]
18. The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
Siemann DW
Br J Cancer Suppl; 1996 Jul; 27():S65-9. PubMed ID: 8763849
[TBL] [Abstract][Full Text] [Related]
19. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
el-Said A; Menke D; Dorie MJ; Brown JM
Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
